Search Result

Results for "

ALK

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Anaplastic lymphoma kinase (ALK) (190) Ack1 (1) ADC Antibody (1) Akt (11) AMPK (3) Apoptosis (40) Autophagy (14) Bacterial (1) BCRP (1) Biochemical Assay Reagents (24) BRK (1) c-Kit (1) c-Met/HGFR (16) Cadherin (2) Casein Kinase (1) Caspase (3) CCR (2) CDK (4) Checkpoint Kinase (Chk) (1) Cytochrome P450 (1) DNA-PK (1) Drug Derivative (1) Drug Isomer (1) E3 Ligase Ligand-Linker Conjugates (1) EGFR (13) ERK (6) FAK (7) FLT3 (2) Fluorescent Dye (6) Glycosidase (1) HDAC (2) HyT (5) IGF-1R (11) IKK (1) Insulin Receptor (9) Integrin (2) Interleukin Related (4) Isotope-Labeled Compounds (16) JAK (3) JNK (3) Keap1-Nrf2 (2) Ligands for E3 Ligase (2) Ligands for Target Protein for PROTAC (5) Microtubule/Tubulin (1) Mitochondrial Metabolism (2) Molecular Glues (1) Mps1 (1) mTOR (5) Mucin (1) NADPH Oxidase (1) NF-κB (2) Notch (1) Opioid Receptor (4) Orexin Receptor (OX Receptor) (2) Organoid (17) p38 MAPK (4) PARP (3) Phosphatase (1) PI3K (4) Pim (1) PROTAC Linkers (3) PROTACs (27) Reactive Oxygen Species (ROS) (1) Reference Standards (26) RIP kinase (3) ROS Kinase (30) SARS-CoV (1) Small Interfering RNA (siRNA) (3) Src (1) STAT (9) TAM Receptor (1) Target Protein Ligand-Linker Conjugates (2) TGF-beta/Smad (15) TGF-β Receptor (98) Tie (1) Toll-like Receptor (TLR) (1) Trk Receptor (13) TSSK (2) VEGFR (2)
By Research Areas:	Cancer (274) Cardiovascular Disease (8) Endocrinology (4) Infection (5) Inflammation/Immunology (43) Metabolic Disease (21) Neurological Disease (18)
Click Chemistry:	Labeling and Fluorescence Imaging (1) PROTAC Synthesis (2) Azide (1) Alkynes (33)
Oligonucleotides:	Rat Pre-designed siRNA Sets (1) Mouse Pre-designed siRNA Sets (1) Human Pre-designed siRNA Sets (1) siRNAs (3)

357

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Click Chemistry

Oligonucleotides

GMP Molecules

Targets Recommended: Anaplastic lymphoma kinase (ALK)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-W040304

Alkynyl Palmitic Acid 3 Publications Verification ALK-C16	PROTAC Linkers	Cancer
Alkynyl Palmitic Acid (Alk-C16) is an alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs . Alkynyl Palmitic Acid is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-131442

Alkyne-phenol 3 Publications Verification ALKyne tyramide; ALK-Ph	Biochemical Assay Reagents	Others
Alkyne-phenol (Alk-Ph) is a clickable ascorbate peroxidase 2 (APEX2) probe. Alkyne-phenol substantially improves APEX-labeling efficiency in intact yeast cells, as it is more cell wall-permeant than APEX2 substrate biotin-phenol (BP). Alkyne-phenol also facilitates the identification of APEX-labeling sites, allowing the unambiguous assignment of membrane topology of mitochondrial proteins . Alkyne-phenol is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-15609

AZD-3463 1 Publications Verification ALK/IGF1R inhibitor	IGF-1R Anaplastic lymphoma kinase (ALK) Autophagy Apoptosis	Endocrinology Cancer
AZD-3463 (ALK/IGF1R inhibitor) is an orally active *ALK/IGF1R* inhibitor, with a K_i of 0.75 nM for ALK. AZD3463 induces apoptosis and autophagy in neuroblastoma cells .

HY-172412

Alixorexton ALKS 2680	Orexin Receptor (OX Receptor)	Neurological Disease
Alixorexton (ALKS 2680) is an orally bioavailable, blood-brain barrier-permeable OX2R-selective activator and wake-promoting agent. Alixorexton can be used for the research of narcolepsy and idiopathic hypersomnia .

HY-13464

ALK-IN-1 Brigatinib analog	Anaplastic lymphoma kinase (ALK) EGFR	Cancer
ALK-IN-1 is an orally active, blood-brain barrier-permeable *ALK* and EGFR inhibitor. ALK-IN-1 binds to and inhibits ALK kinase, ALK fusion proteins, and wild-type and mutant EGFR variants, thereby disrupting their corresponding signaling pathways. ALK-IN-1 can suppress the growth and proliferation of tumor cells and exhibits potential inhibitory activity against mutant EGFR. ALK-IN-1 can be used in the research of non-small-cell lung cancer .

HY-P99752

Nemvaleukin alfa ALKS 4230; RDB-1450	Interleukin Related	Inflammation/Immunology Cancer
Nemvaleukin alfa (ALKS 4230) is a IL-2 fusion protein that selectively binds to intermediate-affinity IL-2R. Nemvaleukin alfa is an activator of NK and effector T cells. Nemvaleukin alfa can be used for research of cancer .

HY-117887

Fidrisertib BLU-782; IPN-60130; ALK2-IN-1	TGF-β Receptor	Cancer
Fidrisertib (BLU-782) is the orally active inhibitor for activin receptor-like kinase 2 (ALK2) that inhibits ALK2 ^R206H, *ALK2, ALK1, ALK6, ALK3, ALK4, TGFβR2* and *ALK5* with IC₅₀s of 0.2, 0.6, 3, 24, 45, 65, 67 and 155 nM, respectively .

HY-15358

ALK inhibitor 2	Anaplastic lymphoma kinase (ALK) FAK TSSK	Cancer
ALK inhibitor 2 (compound 18) is a potent pyrimidin *ALK* inhibitor. ALK inhibitor 2 is a potent inhibitor of testis-specific serine/threonine kinase 2 (TSSK2; IC₅₀=37 nM) and focal adhesion kinase (FAK; IC₅₀=5 nM) .

HY-136788

ALK4290 AKST4290; BI144807	CCR	Neurological Disease Inflammation/Immunology Cancer
ALK4290 (AKST4290) is a potent, orally active and selective CCR3 inhibitor with a Ki of 3.2 nM. ALK4290 blocks CCR3-mediated signaling, abrogates macrophage supernatant-driven mesothelial-to-mesenchymal transition, and decreases p38 phosphorylation. ALK4290 inhibits CCL26-CCR3 axis-driven GPX2-mediated B-cell activation, and targets B cells to inhibit activation by GPX2-overexpressing tumor cells. ALK4290 can be used for the research of hepatocellular carcinome and Parkinson’s disease .

HY-100375

Diroximel fumarate 4 Publications Verification ALKS 8700; BIIB098	Keap1-Nrf2	Inflammation/Immunology
Diroximel fumarate (ALKS 8700) is an orally-active and well-tolerated monomethyl fumarate (MMF) proagent in a controlled-release formulation. Diroximel fumarate is considered as active equivalent to its active metabolite dimethyl fumarate (DMF). Diroximel fumarate has a favorable safety and efficacy profile, has the potential for the study of multiple sclerosis (MS). Diroximel fumarate is a Nrf2 activator that alleviate MGO-induced pain hypersensitivity .

HY-15357

ALK inhibitor 1 1 Publications Verification	Anaplastic lymphoma kinase (ALK) FAK TSSK	Cancer
ALK inhibitor 1 (compound 17) is a potent pyrimidin *ALK* inhibitor. ALK inhibitor 1 is a potent inhibitor of testis-specific serine/threonine kinase 2 (TSSK2; IC₅₀=31 nM) and focal adhesion kinase (FAK; IC₅₀=2 nM) .

HY-123689

Samidorphan ALKS-33; RDC-0313	Opioid Receptor	Neurological Disease
Samidorphan (ALKS-33) is an orally active opioid system modulator that has a high affinity for binding with μ‐opioid, κ‐opioid, and δ‐opioid receptors. Samidorphan acts as an antagonist at μ‐opioid receptors and acts as a partial agonist at k-opioid and δ‐opioid receptors. Samidorphan primarily acts as an opioid receptor antagonist in vivo. Samidorphan can improve the behavior of depressed animals .

HY-151289

ALK5-IN-34	TGF-β Receptor TGF-beta/Smad	Cancer
ALK5-IN-34 is an selective orally active activin receptor-like kinase (ALK) inhibitor. ALK5-IN-34 can inhibit the activity of ALK5-IN-34 with an IC₅₀ value of ≤10 nM. ALK5-IN-34 also has inhibitory of tumor growth and can be used for the research of proliferative diseases, such as cancer .

HY-144043

ALK5-IN-8	TGF-β Receptor	Cancer
ALK5-IN-8 is a potent inhibitor of TGFβRI (ALK5). ALK5-IN-8 Inhibits the phosphorylation of ALK5 on its downstream signaling proteins (Smad2 or Smad3) by blocking the binding of TGFβRI to ligands, thereby affecting or blocking TGF-β signaling. ALK5-IN-8 has the potential for the research of various ALK5-mediated related diseases (extracted from patent WO2021190425A1, compound 1) .

HY-112815

ALK2-IN-2 1 Publications Verification	TGF-β Receptor	Cardiovascular Disease Inflammation/Immunology
ALK2-IN-2 is an orally active and selective inhibitor of *ALK2* (ACVR1), with an IC₅₀ value of 9 nM, and over 700-fold selectivity against ALK3. ALK2-IN-2 can inhibit oxidative stress and protect endothelial cells .

HY-136773

KER047 ALK2-IN-4	TGF-β Receptor	Metabolic Disease
KER047 (ALK2-IN-4) is a potent activin receptor-like kinase-2 (ALK2) inhibitor. KER047 can be used for the research of metabolic disease, such as fibrodysplasia ossificans progressiva (FOP).

HY-19990

ALK kinase inhibitor-1	Anaplastic lymphoma kinase (ALK)	Cancer
ALK kinase inhibitor-1 is an anaplastic lymphoma kinase (ALK) inhibitor extracted from patent US20130261106A1 compound I-202 .

HY-N0679S

Retinyl acetate-d3 ALK-001; Retinol acetate-d₃; Vitamin A acetate-d₃	Isotope-Labeled Compounds	Metabolic Disease
Retinyl acetate-d₃ (ALK-001) is a deuterated Vitamin A. Retinyl acetate-d₃ can be used for research of geographic atrophy (GA) secondary to age-related macular degeneration (AMD) .

HY-156432

ALK-IN-26	Anaplastic lymphoma kinase (ALK) mTOR PARP Caspase	Cancer
ALK-IN-26 is an ALK inhibitor with IC₅₀ value of 7.0 μM for ALK tyrosine kinase. ALK-IN-26 has good pharmacokinetic properties and blood-brain barrier (BBB) permeability. ALK-IN-26 can induce apoptosis, autophagy and necrosis. ALK-IN-26 can be used in glioblastoma studies .

HY-151275

ALK5-IN-28	TGF-β Receptor TGF-beta/Smad	Cancer
ALK5-IN-28 (Compound Ex-05) is a selective *ALK-5* inhibitor (IC₅₀ ≤ 10 nM) that inhibits TGF-β-induced SMAD signaling. ALK5-IN-28 has the potential to inhibit tumor growth in vivo. ALK5-IN-28 can be used in the research of proliferative diseases such as cancer .

HY-160520

ALK-IN-28	Anaplastic lymphoma kinase (ALK)	Cancer
ALK-IN-28 (compound 22) is an inhibitor of anaplastic lymphoma kinase (ALK) .

HY-W754809

ALK ligand-1	Ligands for Target Protein for PROTAC Anaplastic lymphoma kinase (ALK)	Cancer
ALK ligand-1 is a *ALK* ligand that can be used for synthesis of PROTAC ALK degrader-4 (HY-175527) .

HY-176941

ALK2-IN-6	TGF-β Receptor	Cancer
ALK2-IN-6 (Compound 14a) is a selective *ALK2* inhibitor, with an IC₅₀ of 9 nM. ALK2-IN-6 can be used in the research of diffuse intrinsic pontine glioma .

HY-151283

ALK5-IN-33	TGF-β Receptor	Cancer
ALK5-IN-33 (Compound EX-10) is a selective, orally active *ALK-5* inhibitor with an IC₅₀ ≤10 nM .

HY-178231

ALK5-IN-85	TGF-β Receptor	Inflammation/Immunology Cancer
ALK5-IN-85 (Compound 19) is a TGFβRI (ALK5) inhibitor with an IC₅₀ < 100 ?nM. ALK5-IN-85 can be used for respiratory diseases including idiopathic pulmonary fibrosis, asthma, COPD and lumg cancer, and dermal and ocular fibrotic conditions research .

HY-172412A

Alixorexton enantiomer ALKS 2680 enantiomer	Orexin Receptor (OX Receptor)	Neurological Disease
Alixorexton (ALKS 2680) enantiomer is the enantiomer of Alixorexton (HY-172412). Alixorexton is a selective, orally active and brain-penetrant agonist for orexin-2 receptor and can be used for hypersomnias research .

HY-131244

ALK-IN-9	Anaplastic lymphoma kinase (ALK)	Cancer
ALK-IN-9 (compound 40) is a potent *ALK* inhibitor. ALK-IN-9 inhibits cell proliferation with IC₅₀s of <0.2 nM, <0.2 nM, 0.2 nM for Ba/F3-EML4-ALK, KM 12 (TPM3-TRKA), KG-l cell (OP2-FGFR1), respectively .

HY-146408

ALK-IN-21	Anaplastic lymphoma kinase (ALK)	Cancer
ALK-IN-21 (Compound B10), a potent *ALK* inhibitor for ALKG1202R mutation, exhibits remarkable enzymatic inhibitory potency with IC₅₀ values of 4.59 nM, 2.07 nM and 5.95 nM toward ALK ^WT, ALK ^L1196M and ALK ^G1202R, respectively. ALK-IN-21 efficiently inhibits the proliferation of ALK-positive Karpas299 and H2228 cells both with IC₅₀ values of 0.07 μM. ALK-IN-21 can be used for the research of anaplastic large cell lymphoma .

HY-175527

ALK degrader 2	HyT Anaplastic lymphoma kinase (ALK) Apoptosis	Cancer
ALK degrader 2 is an orally active *ALK* degrader that degrades *EML4-ALK* levels (DC₅₀ = 8 nM) and nucleophosmin *(NPM)-ALK* protein levels (DC₅₀ = 102 nM). ALK degrader 2 mediates *ALK* degradation via the Hsp70 chaperone system and ubiquitin-proteasome pathway. ALK degrader 2 induces significant S-phase cell cycle arrest and apoptosis in H3122 cells. ALK degrader 2 shows anti-tumor activity in mice bearing H3122 xenografts. ALK degrader 2 can be used for the study of non-small cell lung cancer (NSCLC). (Pink: ALK ligand (HY-W754809), Blue: Hyt (HY-W013021), Black: Linker (HY-Y1760), ALK ligand-linker conjugate (HY-175528)) .

HY-175849

ALK degrader 1	HyT Anaplastic lymphoma kinase (ALK) Apoptosis STAT	Cancer
ALK degrader 1 is a potent, hydrophobic tag (HyT)-based degrader that induces ubiquitin-proteasome system (UPS)-dependent *EML4-ALK* degradation (DC₅₀ = 0.13 μM). ALK degrader 1 demonstrates potent ALK degradation and antiproliferative effects in ALK-dependent cell lines, while showing minimal cytotoxicity in ALK fusion-negative cells. ALK degrader 1 triggers cell cycle arrest at the G0/G1 phase and stimulates apoptosis. ALK degrader 1 not only facilitates efficient degradation of the ALK protein but also disrupts key downstream effectors, including the STAT3 signaling axis. ALK degrader 1 mediates robust EML4-ALK degradation in vivo. ALK degrader 1 can be used for ALK-related diseases research .

HY-144437

ALK5-IN-9	TGF-β Receptor	Cancer
ALK5-IN-9 (Compound 8h) is a potent and orally active inhibitor of TGFβRI (ALK5). ALK5-IN-9 inhibits ALK5 autophosphorylation and NIH3T3 cell activity with IC₅₀ values of 25 nM and 74.6 nM, respectively. ALK5-IN-9 also shows favorable pharmacokinetic profile and ameliorated hERG inhibition. ALK5-IN-9 has the potential for the research of cancer disease .

HY-161662

ALK5-IN-80	TGF-β Receptor	Cancer
ALK5-IN-80 (Compound 29b) is a selective *ALK5* inhibitor with an IC₅₀ value of 3.7 nM. ALK5-IN-80 can be used for cancer research .

HY-161749

*PROTAC ALK* degrader-1**	PROTACs Anaplastic lymphoma kinase (ALK)	Cancer
PROTAC ALK degrader-1 (compound B1) is an *ALK* degrader based on PROTACs, with the DC₅₀ of 26 nM in H3122 EML4-ALK. PROTAC ALK degrader-1 can be used to synthesis PROTAC ALK degrader-2 (HY-161750) with superior bioavailability .

HY-160172

ALK/ROS1-IN-4	Anaplastic lymphoma kinase (ALK) ROS Kinase	Cancer
ALK/ROS1-IN-4 (example 13) is a dual inhibitor of *ALK* and ROS1 kinase .

HY-147833

ALK-IN-22	Anaplastic lymphoma kinase (ALK) Apoptosis	Cancer
ALK-IN-22 (compound I-24) is a potent *ALK* inhibitor with IC₅₀ values of 2.3, 3.7 and 2.9 nM for ALK, ALK ^L1196M and ALK ^G1202R, respectively. ALK-IN-22 down-regulated the phosphorylation of ALK and its downstream proteins. ALK-IN-22 induces apoptosis. ALK-IN-22 can be used for tumor research .

HY-144732

*TRK/ALK-IN-1*	Trk Receptor Anaplastic lymphoma kinase (ALK)	Cancer
TRK/ALK-IN-1 (compound 21) is a potent and dual inhibitor of TRK and *ALK. TRK/ALK-IN-1 in the enzymatic assays is in good accordance with anti-proliferative activity with IC₅₀* values of 2.2, 9.3 and 38 nM towards TRKA, ALK ^WT and ALK ^L1196M, respectively. TRK/ALK-IN-1 has the potential for the research of cancer diseases .

HY-168551

*PROTAC ALK* degrader-3**	PROTACs Anaplastic lymphoma kinase (ALK)	Cancer
PROTAC ALK degrader-3 (4B) is an orally active *ALK* degrader based on PROTACs, which can effectively induce persistent degradation of ALK fusion protein in Karpas 299 cells and strong inhibition of downstream pathways,IC₅₀ is 119.33 nM. PROTAC ALK degrader-3 exhibits antitumor activity. (Structure Note: PINK, ALK Inhibitor (HY-15656); Blue, E3 (HY-W023573); Black, linker (HY-168552)) .

HY-123689S1

Samidorphan-d5 ALKS-33-d₅; RDC-0313-d₅	Isotope-Labeled Compounds Opioid Receptor	Neurological Disease
Samidorphan-d5 (ALKS-33-d5) is is a deuterated compound of Samidorphan. Samidorphan is an orally active opioid system modulator that binds with high affinity to μ-opioid, κ-opioid, and δ-opioid receptors. Samidorphan is a μ-opioid receptor antagonist and a partial agonist at k-opioid and δ-opioid receptors. Samidorphan acts primarily as an opioid receptor antagonist in vivo .

HY-13464R

ALK-IN-1 (Standard) Brigatinib analog (Standard)	Reference Standards Anaplastic lymphoma kinase (ALK) EGFR	Cancer
ALK-IN-1 (Standard) is the analytical standard of ALK-IN-1 (Brigatinib analog) (HY-13464). This product is intended for research and analytical applications. ALK-IN-1 is an *ALK* and EGFR inhibitor. ALK-IN-1 binds to and inhibits ALK kinase, ALK fusion proteins, and wild-type and mutant EGFR variants, thereby disrupting their corresponding signaling pathways. ALK-IN-1 can suppress the growth and proliferation of tumor cells and exhibits potential inhibitory activity against mutant EGFR. ALK-IN-1 can be used in the research of non-small-cell lung cancer .

HY-175528

ALK ligand-Linker Conjugate 1	Target Protein Ligand-Linker Conjugates Anaplastic lymphoma kinase (ALK)	Cancer
ALK ligand-Linker Conjugate 1 is a *ALK* ligand-linker conjugate that can be used for synthesis of PROTAC ALK degrader-4 (HY-175527) .

HY-157391

ALK/ROS1-IN-3	ROS Kinase Anaplastic lymphoma kinase (ALK)	Cancer
ALK/ROS1-IN-3 (compound C01) is a ROS1 and *ALK* dual inhibitor with IC₅₀s of 42.3 nM and 49.1 nM for ROS1 ^G2032R and ALK ^G1202R, respectively .

HY-173493

ALK-IN-31	Anaplastic lymphoma kinase (ALK) Apoptosis Akt mTOR	Cancer
ALK-IN-31 (Compound Ld-10) is an orally active *ALK* inhibitor (IC₅₀: 1135 nM). ALK-IN-31 exhibits excellent antiproliferative activity against lung cancer H2228 cells with an IC₅₀ value of 1.35 μM. ALK-IN-31 induces apoptosis and arrests cell proliferation in the G0/G1 phase by affecting mitochondrial function. ALK-IN-31 exerts its anti-tumor effect by downregulating the expression of p-AKT and p-mTOR in the PI3K-AKT-mTOR signaling pathway downstream of ALK. ALK-IN-31 can be used in the study of non-small cell lung cancer (NSCLC) .

HY-161350

ALK/HDAC-IN-1	Anaplastic lymphoma kinase (ALK) HDAC	Cancer
ALK/HDAC-IN-1 is a dual inhibitor for *ALK* and HDAC6, with IC₅₀s of 16 nM and 1.03 μM, respectively. ALK/HDAC-IN-1 exhibits antitumor activity .

HY-151273

ALK5-IN-27	TGF-β Receptor	Cancer
ALK5-IN-27 (Compound EX-04) is a potent *ALK-5* inhibitor with an IC₅₀ ≤10 nM. ALK5-IN-27 also inhibits *ALK-2* (selectivity ALK2/ALK5 ≤10) .

HY-151270

ALK5-IN-25	TGF-β Receptor	Cancer
ALK5-IN-25 (compound EX-02) is a potent *ALK-5* inhibitor with an IC₅₀ ≤10 nM.ALK5-IN-25 also inhibits *ALK-2* (selectivity ALK2/ALK5≤10). ALK5-IN-25 can be used for the research of cancer .

HY-153246

ALK2-IN-5	Anaplastic lymphoma kinase (ALK)	Cancer
ALK2-IN-5, pyrazolopyrimidine compound, is an *ALK2* inhibitor. ALK2-IN-5 can inhibit ALK2 activity and FGFR activity. ALK2-IN-5 can be used for the research of disorders associated with ALK2 activity and/or FGFR activity, such as cancer .

HY-112877

ALK-5-IN-1	TGF-β Receptor	Cancer
ALK-5-IN-1 is an *ALK-5* inhibitor. ALK-5-IN-1 can be used for the research of cancer, and conditions involving fibrosis .

HY-151272

ALK5-IN-26	Anaplastic lymphoma kinase (ALK)	Cancer
ALK5-IN-26 (EX-22) is an *ALK* (Activin receptor-like kinase) inhibitor. ALK5-IN-26 inhibits ALK5 with an IC₅₀ value ≤10 nM. ALK5-IN-26 can be used for the research of cancer .

HY-159952

ALK5-IN-84	Anaplastic lymphoma kinase (ALK)	Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer
ALK5-IN-84 (Compound 23) is an ALK5 inhibitor with a pK_i value of 9.35 against hALK5. When administered via inhalation, ALK5-IN-84 exhibits significant *ALK5* inhibitory activity. ALK5-IN-84 is promising for the development of inhaled *ALK5* inhibitors .

HY-128596

ALK-IN-6	Anaplastic lymphoma kinase (ALK)	Cancer
ALK-IN-6 (compound 11) is an orally bioavailable inhibitor of anaplastic lymphoma kinase (ALK), with IC₅₀ values of 71 nM, 18.72 nM and 36.81 nM for ALK wild, ALK F1196M and ALK F1174L, respectively .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N4107

Phyllanthin 1 Publications Verification	Phyllanthus urinaria Linn. Classification of Application Fields Lignans Metabolic Disease Euphorbiaceae Phenylpropanoids Plants Disease Research Fields Source Classification	TGF-beta/Smad
Phyllanthin is an effective oral anticancer agent. Phyllanthin inhibits MOLT-4 cell viability, increases apoptosis, inhibits cell migration and invasion. Phyllanthin exerts anti-fibrotic effects by down-regulating TGF signaling pathway via ALK5 and Smad2/3. Phyllanthin also has anti-inflammatory and antibacterial properties .

HY-N1510

Kaempferol 3-O-gentiobioside	Flavonols Structural Classification Flavonoids Sauropus spatulifolius Beille Classification of Application Fields Phenols Polyphenols Metabolic Disease Euphorbiaceae Plants Disease Research Fields Source Classification	Glycosidase Notch Toll-like Receptor (TLR) NF-κB Mucin Reactive Oxygen Species (ROS) Bacterial TGF-beta/Smad Anaplastic lymphoma kinase (ALK)
Kaempferol 3-O-gentiobioside is an orally active flavonoid, with a K_a value of 57 µM against human NOTCH1 and an IC₅₀ value of 50 μM against α-glucosidase. Kaempferol 3-O-gentiobioside inhibits the NOTCH signaling pathway. It downregulates the expression of TLR4 and NLRP3, and suppresses the activation and nuclear translocation of NF-κB. Kaempferol 3-O-gentiobioside inhibits the expression of MUC5AC, reduces nitrite and ROS levels, and attenuates excessive mucus secretion. It exhibits antibacterial activity, reducing the formation and growth of MRSA biofilms. Kaempferol 3-O-gentiobioside blocks the *TGF-β/ALK5/Smad* signaling pathway and inhibits epithelial-mesenchymal transition. It suppresses the proliferation, migration, invasion and metastatic growth of tumor cells. Kaempferol 3-O-gentiobioside alleviates airway inflammation and mucus hypersecretion in mice with allergic asthma . It reduces the volume of ovarian cancer xenografts in mice. Kaempferol 3-O-gentiobioside can be used in research related to allergic asthma, diabetes, MRSA infection, breast cancer, gastric cancer and ovarian cancer .

HY-N4126

6-Demethoxytangeretin 1 Publications Verification	Structural Classification Neurological Disease Classification of Application Fields Flavones Rutaceae Plants Citrus reticulata Blanco Flavonoids other families Inflammation/Immunology Disease Research Fields Source Classification Cancer	Anaplastic lymphoma kinase (ALK) p38 MAPK Interleukin Related ERK JNK JAK STAT Akt
6-Demethoxytangeretin is a flavonoid compound that can be isolated from Citrus reticulata. 6-Demethoxytangeretin has anti-inflammatory and anti-allergic activities and can inhibit the production of IL-6 and the expression of related genes in human mast cells through the *ALK* and MAPK pathways. 6-Demethoxytangeretin can promote CRE-mediated transcription in hippocampal neurons .

HY-N12973

Peonidin 3-arabinoside	Structural Classification Phenols Polyphenols Ericaceae Plants Vaccinium uliginosum L. Source Classification	Anaplastic lymphoma kinase (ALK)
Peonidin 3-arabinoside is an anthocyanin found in vaccinium mytrillus. Peonidin 3-arabinoside binds to the ALK5 and has anticancer activity. Peonidin 3-arabinoside also has antioxidant, anti-inflammatory, and anti-urinary tract infection properties .

HY-N4107R

Phyllanthin (Standard)	Phyllanthus urinaria Linn. Structural Classification Lignans Euphorbiaceae Phenylpropanoids Plants Source Classification	Reference Standards TGF-beta/Smad
Phyllanthin (Standard) is the analytical standard of Phyllanthin. This product is intended for research and analytical applications. Phyllanthin is an effective oral anticancer agent. Phyllanthin inhibits MOLT-4 cell viability, increases apoptosis, inhibits cell migration and invasion. Phyllanthin exerts anti-fibrotic effects by down-regulating TGF signaling pathway via ALK5 and Smad2/3. Phyllanthin also has anti-inflammatory and antibacterial properties .

Cat. No.	Product Name	Chemical Structure

HY-13011S

Alectinib-d8
Alectinib-d₈ is the deuterium labeled Alectinib. Alectinib (CH5424802) is a potent, selective, and orally available ALK inhibitor with an IC₅₀ of 1.9 nM and a Kd value of 2.4 nM (in an ATP-competitive manner), and also inhibits ALK F1174L and ALK R1275Q with IC₅₀s of 1 nM and 3.5 nM, respectively . Alectinib demonstrates effective central nervous system (CNS) penetration .

HY-N0679S

Retinyl acetate-d3
Retinyl acetate-d₃ (ALK-001) is a deuterated Vitamin A. Retinyl acetate-d₃ can be used for research of geographic atrophy (GA) secondary to age-related macular degeneration (AMD) .

HY-50878S

Crizotinib-d5

Crizotinib-d₅ is the deuterium labeled Crizotinib. Crizotinib (PF-02341066) is an orally bioavailable, ATP-competitive ALK and c-Met inhibitor with IC₅₀s of 20 and 8 nM, respectively. Crizotinib inhibits tyrosine phosphorylation of NPM-ALK and tyrosine phosphorylation of c-Met with IC₅₀s of 24 and 11 nM in cell-based assays, respectively. Crizotinib is also a ROS1 inhibitor. Crizotinib has effective tumor growth inhibition .

HY-12215S2

Deulorlatinib
Deulorlatinib (compound A), a deuterated derivative of Lorlatinib (HY-12215), is a potent inhibitor of tyrosine kinase demonstrating the potential for the research of ALK-positive advanced NSCLC .

HY-12678S1

Entrectinib-d8

Entrectinib-d8 (NMS-E628-d8; RXDX-101-d8) is a deuterated version of Entrectinib (HY-12678). Entrectinib (NMS-E628) is an orally available, blood-brain barrier permeable, central nervous system active TrkA/B/C, ROS1 and ALK inhibitor with IC₅₀ values of 1, 3, 5, 12 and 12, respectively. 7 nM. Entrectinib induces apoptosis and cycle arrest in cancer cells, has anti-tumor activity, and also alleviates bleomycin-induced pulmonary fibrosis in mice .

HY-15656S

Ceritinib-d7

Ceritinib (LDK378)-d₇ is a deuterium labeled Ceritinib (HY-15656). Ceritinib is a selective, orally bioavailable and ATP-competitive ALK tyrosine kinase inhibitor . Ceritinib is a selective, orally bioavailable, and ATP-competitive ALK tyrosine kinase inhibitor with an IC₅₀ of 200 pM. Ceritinib also inhibits IGF-1R, InsR, and STK22D with IC₅₀ values of 8, 7, and 23 nM, respectively. Ceritinib shows great antitumor potency .

HY-13011S1

Alectinib-d6
Alectinib-d₆ is deuterium labeled Alectinib. Alectinib (CH5424802) is a potent, selective, and orally available ALK inhibitor with an IC₅₀ of 1.9 nM and a Kd value of 2.4 nM (in an ATP-competitive manner), and also inhibits ALK F1174L and ALK R1275Q with IC₅₀s of 1 nM and 3.5 nM, respectively . Alectinib demonstrates effective central nervous system (CNS) penetration .

HY-123689S1

Samidorphan-d5

Samidorphan-d5 (ALKS-33-d5) is is a deuterated compound of Samidorphan. Samidorphan is an orally active opioid system modulator that binds with high affinity to μ-opioid, κ-opioid, and δ-opioid receptors. Samidorphan is a μ-opioid receptor antagonist and a partial agonist at k-opioid and δ-opioid receptors. Samidorphan acts primarily as an opioid receptor antagonist in vivo .

HY-12857S

Brigatinib-13C6
Brigatinib- ¹³C₆ is the ¹³C-labeled Brigatinib. Brigatinib (AP-26113) is a highly potent and selective ALK inhibitor, with an IC₅₀ of 0.6 nM .

HY-50878AS

Crizotinib-d9 hydrochloride

Crizotinib-d₉ hydrochloride is deuterated labeled Crizotinib hydrochloride (HY-50878A). Crizotinib hydrochloride (PF-02341066 hydrochloride) is an orally bioavailable, selective, and ATP-competitive dual ALK and c-Met inhibitor with IC₅₀s of 20 and 8 nM, respectively. Crizotinib hydrochloride (PF-02341066 hydrochloride) inhibits tyrosine phosphorylation of NPM-ALK and tyrosine phosphorylation of c-Met with IC₅₀s of 24 and 11 nM in cell-based assays, respectively. It is also a ROS proto-oncogene 1 (ROS1) inhibitor. Crizotinib hydrochloride (PF-02341066 hydrochloride) has effective tumor growth inhibition .

HY-12678S

Entrectinib-d4

Entrectinib-d4 (NMS-E628-d4; RXDX-101-d4) is the deuterium labeled Entrectinib (HY-12678). Entrectinib is an orally active, BBB-penetrated and centrally active inhibitor of TrkA/B/C, ROS1 and ALK, with IC₅₀ values of 1, 3, 5, 12 and 7 nM, respectively. Entrectinib induces apoptosis and cycle arrest in cancer cells, has antitumor activity, and attenuates bleomycin-induced lung fibrosis in mice .

HY-155227S

ALK/EGFR-IN-1-d5

ALK/EGFR-IN-1-d5 (Compound (-)-9a) is a deuterated dual-target inhibitor of EGFR and ALK, with an IC₅₀ of 1.08 nM for EGFR and an IC₅₀ of 2.395 nM for ALK. ALK/EGFR-IN-1-d5 inhibits the phosphorylated proteins in the EGFR, ALK, and BRK signaling pathways, blocking the cell cycle, leading to a reduction in mitochondrial membrane potential and cell apoptosis (Apoptosis). ALK/EGFR-IN-1-d5 also significantly inhibits tumor growth in animal models and demonstrates good safety. ALK/EGFR-IN-1-d5 holds promise for research in the field of cancer treatment

HY-123689S

Samidorphan-d4

Samidorphan-d4 is the deuterium labeled Samidorphan(HY-123689).Samidorphan (ALKS-33) is an orally active opioid system modulator that has a high affinity for binding with μ‐opioid, κ‐opioid, and δ‐opioid receptors. Samidorphan acts as an antagonist at μ‐opioid receptors and acts as a partial agonist at k-opioid and δ‐opioid receptors. Samidorphan primarily acts as an opioid receptor antagonist in vivo .

HY-50878S2

Crizotinib-d9

Crizotinib-d₉ (PF-02341066-d₉) is deuterium labeled Crizotinib. Crizotinib (PF-02341066) is an orally bioavailable, ATP-competitive ALK and c-Met inhibitor with IC₅₀s of 20 and 8 nM, respectively. Crizotinib inhibits tyrosine phosphorylation of NPM-ALK and tyrosine phosphorylation of c-Met with IC₅₀s of 24 and 11 nM in cell-based assays, respectively. Crizotinib is also a ROS1 inhibitor. Crizotinib has effective tumor growth inhibition .

HY-50878S1

Crizotinib-d8

Crizotinib-d₈ (PF-02341066-d₈) is deuterium labeled Crizotinib. Crizotinib (PF-02341066) is an orally bioavailable, ATP-competitive ALK and c-Met inhibitor with IC₅₀s of 20 and 8 nM, respectively. Crizotinib inhibits tyrosine phosphorylation of NPM-ALK and tyrosine phosphorylation of c-Met with IC₅₀s of 24 and 11 nM in cell-based assays, respectively. Crizotinib is also a ROS1 inhibitor. Crizotinib has effective tumor growth inhibition .

HY-12857S2

Brigatinib-d11
Brigatinib-d₁₁ (AP-26113-d₁₁) is deuterium labeled Brigatinib. Brigatinib (AP-26113) is a highly potent, selective and orally active *ALK* inhibitor, with an IC₅₀ of 0.6 nM. Brigatinib can be used for research of NSCLC .

HY-13012S

RepSox-d5
RepSox-d₅ (E-616452-d₅) is the deuterium labeled RepSox (HY-13012). RepSox (E-616452) is a potent and selective transforming growth factor-beta receptor I/activin like kinase 5 (TGF-β-RI/ALK5) inhibitor. RepSox inhibits ALK5 autophosphorylation with an IC₅₀ value of 4 nM. RepSox can be used for the research of obesity and associated metabolic diseases such as type 2 diabetes .

Targets Recommended: Anaplastic lymphoma kinase (ALK)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-12278G

K02288	TGF-β Receptor	Cancer
K02288 (GMP) is K02288 (HY-12278) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. K02288 is a potent bone morphogenetic protein (BMP) type I receptor inhibitor with IC₅₀s of 1.8, 1.1, 6.4 nM for ALK1, ALK2 and ALK6, respectively. K02288 shows slightly weaker inhibition against ALK3 and ALK6 with IC₅₀s of of 5-34 nM.

HY-10432G

A 83-01	Anaplastic lymphoma kinase (ALK)	Cancer
A 83-01 (GMP) is A 83-01 (HY-10432) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. A 83-01 is a potent *ALK4/5/7* inhibitor .

HY-12071G

LDN193189 DM-3189	Organoid TGF-β Receptor	Cancer
LDN193189 GMP is LDN193189 (HY-12071) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. LDN193189 (DM-3189) is a potent selective BMP type I receptor (BMP I) inhibitor. LDN193189 efficiently inhibits transcriptional activity of the BMP type I receptors *ALK2* and *ALK3* with IC₅₀ values of 5 nM and 30 nM, respectively. LDN193189 can be used for the research of bone morphogenetic protein signalling, such as fibrodysplasia ossificans progressiva .

HY-13012G

RepSox E-616452; SJN 2511	TGF-β Receptor	Metabolic Disease
RepSox (E-616452) (GMP) is a RepSox (HY-13012) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. RepSox is a potent and selective TGF-β-RI/ALK5 inhibitor .

HY-13227G

SD-208	TGF-β Receptor	Cancer
SD-208 (GMP) is SD-208 (HY-13227) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. SD-208 is a selective TGF-βRI (ALK5) inhibitor with IC₅₀ of 48 nM, and > 100-fold selectivity over TGF-βRII.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks